Is Avalo Therapeutics Stock a Good Investment?
Avalo Therapeutics Investment Advice | AVTX |
- Examine Avalo Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Avalo Therapeutics' leadership team and their track record. Good management can help Avalo Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Avalo Therapeutics' business and its evolving consumer preferences.
- Compare Avalo Therapeutics' performance and market position to its competitors. Analyze how Avalo Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Avalo Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Avalo Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Avalo Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Avalo Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Avalo Therapeutics Stock
Researching Avalo Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 65.0% of the company shares are held by institutions such as insurance companies. The book value of Avalo Therapeutics was presently reported as 2.18. The company recorded earning per share (EPS) of 94.42. Avalo Therapeutics had not issued any dividends in recent years. The entity had 1:240 split on the 29th of December 2023.
To determine if Avalo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avalo Therapeutics' research are outlined below:
| Avalo Therapeutics is way too risky over 90 days horizon | |
| Avalo Therapeutics appears to be risky and price may revert if volatility continues | |
| Avalo Therapeutics currently holds 537 K in liabilities with Debt to Equity (D/E) ratio of 5.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avalo Therapeutics has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Avalo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 1.92 M. Net Loss for the year was (31.54 M) with loss before overhead, payroll, taxes, and interest of (7.94 M). | |
| Avalo Therapeutics currently holds about 11.25 M in cash with (30.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2. | |
| Avalo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of Avalo Therapeutics shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Avalo Therapeutics receives 69.4M in proceeds from full exercise of private placement warrants - MSN |
Avalo Therapeutics Quarterly Good Will |
|
Avalo Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avalo Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avalo Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Avalo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Avalo Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-08-14 | 2017-06-30 | -0.22 | -0.14 | 0.08 | 36 | ||
2018-08-09 | 2018-06-30 | -0.1 | -0.19 | -0.09 | 90 | ||
2023-05-04 | 2023-03-31 | -0.97 | -0.85 | 0.12 | 12 | ||
2023-08-03 | 2023-06-30 | -0.8 | -0.59 | 0.21 | 26 | ||
2023-03-29 | 2022-12-31 | -0.73 | -1.04 | -0.31 | 42 | ||
2021-03-08 | 2020-12-31 | -1.8 | -2.16 | -0.36 | 20 | ||
2022-08-04 | 2022-06-30 | -1.77 | -1.38 | 0.39 | 22 | ||
2019-05-09 | 2019-03-31 | -1.96 | -1.56 | 0.4 | 20 |
Know Avalo Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avalo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avalo Therapeutics backward and forwards among themselves. Avalo Therapeutics' institutional investor refers to the entity that pools money to purchase Avalo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 10.1 K | Bank Of America Corp | 2024-06-30 | 5.6 K | Ubs Group Ag | 2024-06-30 | 3.6 K | Royal Bank Of Canada | 2024-06-30 | 590 | Blackrock Inc | 2024-06-30 | 329 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 20.0 | Efficient Wealth Management Llc | 2024-09-30 | 5.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 4.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 2.0 | Ikarian Capital, Llc | 2024-09-30 | 970.4 K | Bvf Inc | 2024-09-30 | 967 K |
Avalo Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 104.53 M.Market Cap |
|
Avalo Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.01) | (3.16) | |
| Return On Capital Employed | (1.43) | (1.50) | |
| Return On Assets | (1.50) | (1.58) | |
| Return On Equity | (4.32) | (4.53) |
Determining Avalo Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Avalo Therapeutics is a good buy. For example, gross profit margin measures Avalo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avalo Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Avalo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Avalo Therapeutics. Check Avalo Therapeutics' Beneish M Score to see the likelihood of Avalo Therapeutics' management manipulating its earnings.
Evaluate Avalo Therapeutics' management efficiency
Avalo Therapeutics has return on total asset (ROA) of (0.3064) % which means that it has lost $0.3064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4252) %, meaning that it created substantial loss on money invested by shareholders. Avalo Therapeutics' management efficiency ratios could be used to measure how well Avalo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.16 in 2024. Return On Capital Employed is likely to drop to -1.5 in 2024. At this time, Avalo Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 16.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 112 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 26.30 | 24.98 | |
| Tangible Book Value Per Share | (11.51) | (10.94) | |
| Enterprise Value Over EBITDA | 0.16 | 0.16 | |
| Price Book Value Ratio | 0.35 | 0.33 | |
| Enterprise Value Multiple | 0.16 | 0.16 | |
| Price Fair Value | 0.35 | 0.33 | |
| Enterprise Value | -4.4 M | -4.1 M |
Understanding the operational decisions made by Avalo Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.034 |
Basic technical analysis of Avalo Stock
As of the 28th of November, Avalo Therapeutics shows the risk adjusted performance of 0.0334, and Mean Deviation of 4.68. Avalo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Avalo Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avalo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avalo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avalo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avalo Therapeutics' Outstanding Corporate Bonds
Avalo Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avalo Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avalo bonds can be classified according to their maturity, which is the date when Avalo Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AZO 475 01 AUG 32 Corp BondUS053332BB79 | View | |
| AZO 45 01 FEB 28 Corp BondUS053332BC52 | View | |
| US053332BA96 Corp BondUS053332BA96 | View | |
| AZO 475 01 FEB 33 Corp BondUS053332BD36 | View | |
| US053332AY81 Corp BondUS053332AY81 | View | |
| AUTOZONE INC Corp BondUS053332AZ56 | View | |
| AUTOZONE INC 375 Corp BondUS053332AV43 | View | |
| US053332AW26 Corp BondUS053332AW26 | View |
Understand Avalo Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Avalo Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0334 | |||
| Market Risk Adjusted Performance | (0.27) | |||
| Mean Deviation | 4.68 | |||
| Semi Deviation | 6.36 | |||
| Downside Deviation | 6.58 | |||
| Coefficient Of Variation | 3106.6 | |||
| Standard Deviation | 6.44 | |||
| Variance | 41.48 | |||
| Information Ratio | 0.0119 | |||
| Jensen Alpha | 0.2826 | |||
| Total Risk Alpha | (0.82) | |||
| Sortino Ratio | 0.0117 | |||
| Treynor Ratio | (0.28) | |||
| Maximum Drawdown | 32.25 | |||
| Value At Risk | (7.94) | |||
| Potential Upside | 12.18 | |||
| Downside Variance | 43.3 | |||
| Semi Variance | 40.46 | |||
| Expected Short fall | (5.04) | |||
| Skewness | (0.37) | |||
| Kurtosis | 1.73 |
| Risk Adjusted Performance | 0.0334 | |||
| Market Risk Adjusted Performance | (0.27) | |||
| Mean Deviation | 4.68 | |||
| Semi Deviation | 6.36 | |||
| Downside Deviation | 6.58 | |||
| Coefficient Of Variation | 3106.6 | |||
| Standard Deviation | 6.44 | |||
| Variance | 41.48 | |||
| Information Ratio | 0.0119 | |||
| Jensen Alpha | 0.2826 | |||
| Total Risk Alpha | (0.82) | |||
| Sortino Ratio | 0.0117 | |||
| Treynor Ratio | (0.28) | |||
| Maximum Drawdown | 32.25 | |||
| Value At Risk | (7.94) | |||
| Potential Upside | 12.18 | |||
| Downside Variance | 43.3 | |||
| Semi Variance | 40.46 | |||
| Expected Short fall | (5.04) | |||
| Skewness | (0.37) | |||
| Kurtosis | 1.73 |
Consider Avalo Therapeutics' intraday indicators
Avalo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Avalo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Avalo Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 7th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 14th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Avalo Stock media impact
Far too much social signal, news, headlines, and media speculation about Avalo Therapeutics that are available to investors today. That information is available publicly through Avalo media outlets and privately through word of mouth or via Avalo internal channels. However, regardless of the origin, that massive amount of Avalo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Avalo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Avalo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Avalo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Avalo Therapeutics alpha.
Avalo Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Avalo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Avalo Therapeutics Corporate Management
| Blake MD | Scientific Advisor | Profile | |
| Barbara Slusher | Founder Board | Profile | |
| Maxim CFA | VP Relations | Profile | |
| Stephen Thomas | VP Discovery | Profile | |
| Christopher Sullivan | Chief Officer | Profile |
Already Invested in Avalo Therapeutics?
The danger of trading Avalo Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avalo Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avalo Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avalo Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.